Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Affimed NV is a biotechnology business based in the US. Affimed shares (AFMD) are listed on the NASDAQ and all prices are listed in US Dollars. Affimed employs 197 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.77 |
|---|---|
| 52-week range | $2.23 - $8.64 |
| 50-day moving average | $3.28 |
| 200-day moving average | $4.84 |
| Wall St. target price | $11.84 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.66 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.77 from 2022-06-30
| 1 week (2022-06-23) | -2.46% |
|---|---|
| 1 month (2022-06-01) | -11.50% |
| 3 months (2022-04-01) | -40.94% |
| 6 months (2021-12-31) | -49.82% |
| 1 year (2021-07-01) | -63.12% |
|---|---|
| 2 years (2020-07-01) | -41.44% |
| 3 years (2019-07-01) | 2.97 |
| 5 years (2017-06-30) | 35.12% |
| Revenue TTM | $38.3 million |
|---|---|
| Gross profit TTM | $41.8 million |
| Return on assets TTM | -20.74% |
| Return on equity TTM | -52.82% |
| Profit margin | -197.47% |
| Book value | $0.95 |
| Market capitalisation | $404.7 million |
TTM: trailing 12 months
We're not expecting Affimed to pay a dividend over the next 12 months.
Over the last 12 months, Affimed's shares have ranged in value from as little as $2.23 up to $8.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Affimed's is 2.4891. This would suggest that Affimed's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Affimed N. V. , a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N. V.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.